Anavex Life Sciences Corp.AVXLNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-18.28%
↓ 72% below average
Average (39q)
-10.61%
Historical baseline
Range
High:51.67%
Low:-190.67%
CAGR
-0.9%
Modest growth trend
| Period | Value |
|---|---|
| Q2 2025 | -18.28% |
| Q1 2025 | 7.56% |
| Q4 2024 | -4.23% |
| Q3 2024 | 4.86% |
| Q2 2024 | -15.82% |
| Q1 2024 | -22.32% |
| Q4 2023 | 15.02% |
| Q3 2023 | 10.05% |
| Q2 2023 | 13.94% |
| Q1 2023 | -1.04% |
| Q4 2022 | 9.22% |
| Q3 2022 | -15.55% |
| Q2 2022 | -18.48% |
| Q1 2022 | 4.08% |
| Q4 2021 | 7.13% |
| Q3 2021 | -15.11% |
| Q2 2021 | -24.83% |
| Q1 2021 | -3.82% |
| Q4 2020 | -31.68% |
| Q3 2020 | 8.05% |
| Q2 2020 | 10.36% |
| Q1 2020 | -9.78% |
| Q4 2019 | -69.94% |
| Q3 2019 | 45.17% |
| Q2 2019 | 11.66% |
| Q1 2019 | -9.20% |
| Q4 2018 | -26.58% |
| Q3 2018 | -103.33% |
| Q2 2018 | 40.05% |
| Q1 2018 | -17.07% |
| Q4 2017 | 21.26% |
| Q3 2017 | -42.80% |
| Q2 2017 | -133.05% |
| Q1 2017 | 50.78% |
| Q4 2016 | 51.67% |
| Q3 2016 | -190.67% |
| Q2 2016 | -10.29% |
| Q1 2016 | 48.65% |
| Q4 2015 | 26.16% |
| Q3 2015 | -26.32% |